Skip to main content

Incidence of Abnormal Metabolic Parameters and Weight Gain Induced by Atypical Antipsychotics in Elderly Patients with Dementia Research and Reports

Buy Article:

$27.00 plus tax (Refund Policy)

Objective: To determine if atypical antipsychotic therapy leads to the development of abnormal metabolic parameters and weight gain in elderly patients with dementia.

Design: Retrospective chart review.

Setting: Veterans Affairs Medical Center.

Patients: Veterans 65 years of age or older with the diagnosis of dementia.

Main Outcome Measure: The incidence of impaired fasting glucose (> 100 mg/dL) after initiation of atypical antipsychotic therapy. The secondary objectives were to determine the incidence of significant weight gain, worsening of lipid values, new onset of type 2 diabetes mellitus, and metabolic syndrome.

Results: After reviewing 979 charts for inclusion and exclusion criteria, 56 patients were found eligible for the study. More than 50% of patients were excluded because they were lacking baseline or follow-up glucose laboratory results. Ten percent of the study population developed impaired fasting glucose after starting atypical antipsychotic therapy. Overall glucose increased by 9.7 mg/dL from baseline to follow-up. Significant weight gain (≥ 7% of baseline weight) occurred in 8.92% of elderly. However, overall weight decreased by 1.3 kg during the study periods. Patients who developed worsening lipid parameters or were started on lipid-lowering therapy were 14.5% of the study population even though overall lipid levels improved or remained unchanged.

Conclusion: Periodic monitoring of glucose should be considered for patients with dementia begun on atypical antipsychotics, although aggressive monitoring may be controversial for end-stage dementia. Overall, weight reduction and improvement in lipid parameters were observed in this study. The common metabolic adverse effects noted frequently with atypical antipsychotics may not be as much of a concern with the elderly population.

Abbreviations: CATIE-AD = Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease, CPRS = Computerized Patient Record System, DM = Diabetes mellitus, VA = Veterans Affairs.

Consult Pharm 2009;24:201-9.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Data/Media
No Metrics

Keywords: Atypical antipsychotic; Dementia; Elderly; Impaired fasting glucose; Metabolic syndrome; Weight gain

Document Type: Research Article

Publication date: 2009-03-01

More about this publication?
  • The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Membership Information
  • Information for Advertisers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more